Clinical Trial Update: Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease. [Phase 1, Phase 2]

View source ↗

Summary

A multi-center Phase 1/2a trial evaluating an autologous tumor lysate with yeast cell wall particles and dendritic cells plus standard of care checkpoint inhibi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• autologous tumor lysate (TL) + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine

Snippet

Sponsor: Elios Therapeutics, LLC | Conditions: Metastatic Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-03-12